Elio Gregory Pizzutilo MD , Alberto Giuseppe Agostara MD , Laura Roazzi MD , Rebecca Romanò MD , Valentina Motta PhD , Calogero Lauricella PhD , Giovanna Marrapese PhD , Giulio Cerea MD , Diego Signorelli MD, PhD , Silvio Marco Veronese PhD , Laura Giuseppina Giannetta MD , Andrea Sartore-Bianchi MD , Salvatore Siena MD
{"title":"Repotractinib克服ROS1重排非小细胞肺癌癌症中F2004V耐药性突变的病例报告","authors":"Elio Gregory Pizzutilo MD , Alberto Giuseppe Agostara MD , Laura Roazzi MD , Rebecca Romanò MD , Valentina Motta PhD , Calogero Lauricella PhD , Giovanna Marrapese PhD , Giulio Cerea MD , Diego Signorelli MD, PhD , Silvio Marco Veronese PhD , Laura Giuseppina Giannetta MD , Andrea Sartore-Bianchi MD , Salvatore Siena MD","doi":"10.1016/j.jtocrr.2023.100555","DOIUrl":null,"url":null,"abstract":"<div><p>ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266636432300098X/pdfft?md5=cb2e257dc0f7c9a2548efebc9427216f&pid=1-s2.0-S266636432300098X-main.pdf","citationCount":"1","resultStr":"{\"title\":\"Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report\",\"authors\":\"Elio Gregory Pizzutilo MD , Alberto Giuseppe Agostara MD , Laura Roazzi MD , Rebecca Romanò MD , Valentina Motta PhD , Calogero Lauricella PhD , Giovanna Marrapese PhD , Giulio Cerea MD , Diego Signorelli MD, PhD , Silvio Marco Veronese PhD , Laura Giuseppina Giannetta MD , Andrea Sartore-Bianchi MD , Salvatore Siena MD\",\"doi\":\"10.1016/j.jtocrr.2023.100555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S266636432300098X/pdfft?md5=cb2e257dc0f7c9a2548efebc9427216f&pid=1-s2.0-S266636432300098X-main.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266636432300098X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266636432300098X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
